Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.021
Sell
RSI(14)
39.734
Neutral
STOCH(KDJ)(9,3,3)
22.568
Neutral
ATR(14)
0.117
Low Volatility
CCI(14)
-81.324
Neutral
Williams %R
96.226
Oversold
TRIX(12,20)
-0.254
Sell
StochRSI(14)
0.000
Sell
Search
Annovis Bio Inc
ANVSAdd to Watchlist
1.660USD
-0.095-5.43%
Close 07-24 16:00（ET）Quotes delayed by 15 min
33.51MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-5.43%
5 Days
-4.60%
1 Month
+0.61%
6 Months
-44.85%
Year to Date
-52.02%
1 Year
-42.56%
Key Figures
1.735Open
1.760High
1.03MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
5.12%Turnover Ratio
1.750Prev. Close
1.640Low
1.06MTurnover
LossP/E Static
2.55P/B
0.00%Div Yield TTM
-190.43%ROA
5.50052wk High
1.74Volume Ratio
-24.59MNet Profit
20.19MShares
-1.7185EPS TTM
1.28Beta
-301.13%ROE
1.54152wk Low
6.86%Amplitude
--Gross Margin
33.51MMarket Cap
0.33Reward/Risk
5.23%Risk Rate
Annovis Bio Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
3
analysts
Buy
Current Rating
12.600
Target Price
+620.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Annovis Bio Inc
ANVS
3
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.718
Sell
MA10
1.734
Sell
MA20
1.816
Sell
MA50
1.865
Sell
MA100
2.032
Sell
MA200
2.511
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Annovis Bio Inc Info
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Ticker SymbolANVS
CompanyAnnovis Bio Inc
CEOMaccecchini (Maria L)
Websitehttps://www.annovisbio.com/
Shareholders
Related Instruments
+0.88%
+1.60%
+0.43%
+0.90%
+0.46%
-0.72%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%Popular Instruments
51900.000
+176.000 (+0.34%)
28150.400
-427.600 (-1.50%)
7408.100
-11.800 (-0.16%)
14948.000
-153.000 (-1.01%)
64219.000
-1152.000 (-1.76%)
6264.500
+48.800 (+0.79%)
90.043
-2.069 (-2.25%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4052.350
+2.980 (+0.07%)
FAQs
What is the current price of Annovis Bio Inc (ANVS)?
The current price of Annovis Bio Inc (ANVS) is 1.66.
What is the symbol of Annovis Bio Inc?
The ticker symbol of Annovis Bio Inc is ANVS.
What is the 52-week high of Annovis Bio Inc?
The 52-week high of Annovis Bio Inc is 5.50.
What is the 52-week low of Annovis Bio Inc?
The 52-week low of Annovis Bio Inc is 1.54.
What is the market capitalization of Annovis Bio Inc?
The market capitalization of Annovis Bio Inc is 33.51M.
Is Annovis Bio Inc (ANVS) currently rated as Buy, Hold, or Sell?
According to analysts, Annovis Bio Inc (ANVS) has an overall rating of Buy, with a price target of 12.60.
What is the Earnings Per Share (EPS TTM) of Annovis Bio Inc (ANVS)?
The Earnings Per Share (EPS TTM) of Annovis Bio Inc (ANVS) is -1.40.